The 5 most employed Peptides in Weight Research

Although research into the impact of peptides and the potential they may hold to induce or mitigate weight is not new science, it has received an increased influx of attention in recent years. Over time, studies have suggested that peptides derived from natural proteins may be engineered to interfere with certain metabolic pathways of interest. The peptides we’ll discuss below are the product of those efforts; they’re among the most promising research peptides that have been studied within the study focus of engineering weight in the past decade.

Peptides and Weight

The introduction of peptides as a potential weight-reductor represents a major paradigm change. Former studies centered on raising metabolic rate, or the rate at which calories are expended. This oversimplified method makes no distinction between the calories from fat and those from other tissues, such as muscle. It has been hypothesized that it may induce weight reduction but may not always target fat cells.

Studies suggest that peptides may have manifold potential properties, but one has been spotlighted for its potential to isolate and expel fat in specific areas. Research suggests peptides may employ chemistry to modify calorie use and storage. This may redirect energy expenditure from fat storage to other uses, such as muscle and bone growth. Investigations purport that this “weight loss” process may have two outcomes: it may boost metabolism in adipose tissue while diverting energy from less efficient fat burning to more appropriate bone and muscular growth processes.

Extensive studies have been conducted on the weight loss characteristics of the peptides included in this article. It is important to recognize the breadth of this class of peptides and the diversity of their impact, which may make them well-suited for various research applications.

Growth Hormone Secretagogues

The broad class of growth hormone (GH) secretagogues must be addressed in any discussion of peptides for weight research. These peptides have been purported to increase the anterior pituitary gland’s GH production. It is considered that when GH levels are high, caloric expenditure is more often impacts fat cells, with a converse result suggested in the gain of muscle and bone. High growth hormone levels have been linked to a boost in tissue repair speed and efficiency, and may improve cardiovascular health and bone density, but they also have been linked to an increase in hunger hormone signalling.

There are two main types of growth hormone secretagogues. Analogs of growth hormones, such as Sermorelin and CJC-1295, represent the first kind. The second kind is synthetic analogs of the natural peptide ghrelin, which are believed to act as agonists of the growth hormone secretagogue receptor. Some examples of these peptides include growth hormone-releasing hormones type 2 and 6, Hexarelin, and Ipamorelin. Most studies that led to the development of modern peptides like Semaglutide focused on substances classified as growth hormone secretagogues.

Tirzepatide Peptide

Tirzepatide is a peptide believed to bind with the GLP-1 receptor and the GIP receptor; this makes it a twin-cretin. Like Liraglutide and Semaglutide, Tirzepatide has been hypothesized to improve impact and exhibit unique characteristics. Researchers proposed that for a 15% reduction of total weight, Tirzepatide might be roughly 33 times more likely to do so than conventional GLP-1 receptor agonists. Research also suggests Tirzepatide may suppress hunger hormone signalling by activating the brain’s GLP-1 receptor. Insulin secretion is stimulated while gastrin production is suppressed thanks to its action on the GIP receptor. Inhibition of gastrin slows gastrointestinal motility, increasing satiety and decreasing appetite. Investigations imply that it may also reduce triglycerides, apoC-III, and other lipoproteins, all risk factors for cardiovascular disease.

Semaglutide Peptide

Semaglutide has been hypothesized to stimulate the GLP-1 receptor. Weight research peptides like Semaglutide have been speculated to function in two distinct ways. Semaglutide has been purported to reduce intestinal motility and prolong stomach emptying, resulting in more satiety and less rapid blood sugar spikes. Second, Semaglutide was speculated to decrease appetite and increase signalling of satiety in the brain, impacting the central nervous system, contributing to a reduction in food intake. In experimental studies, Semaglutide was suggested to result in a 5% weight decrease after 6 months. It has been proposed that Semaglutide may lead to an average 15% weight reduction after a year of prolonged exposure in murine models.

MOTS-c Peptide

Because it is considered primarily a mitochondrial peptide, MOTS-c has been speculated to stand out among the others on this list. Mitochondria are intracellular organelles responsible for producing most of the cell’s energy. Even among peptides studied specifically within the context of weight research, MOTS-c is very short, and studies suggest that it may alter many metabolic activities while passing through the cell, mitochondrial, and nuclear membranes. MOTS-c was suggested to stimulate the AMPK pathway, potentially increasing fatty acid and sugar oxidation. MOTS-c seems to control the nucleus’s genes responsible for using glucose and producing antioxidants. In particular, it has been hypothesized that MOTS-c may mediate beta-oxidation to boost lipolysis and inhibit the formation of new fat.

Liraglutide Peptide

Liraglutide is a short, naturally occurring peptide hormone suggested to suppress appetite and hunger by increasing insulin production, delaying stomach emptying, and slowing intestinal motility. However, a neurotransmitter-like effect has been speculated in mice, suggesting that Liraglutide may have a central function in reducing food cravings. Liraglutide does seem very powerful in decreasing hunger, boosting feelings of satiety, and lowering the impulse to consume. Yet, it is not alone among peptides for weight research in this aspect. Liraglutide has been suggested to lower A1C levels (a long-term measure of blood sugar management) and cardiovascular risk factors over the long run.

Visit for more educational articles about research compounds and where to buy them online as a researcher interested in further studying them.


[i] R. Zieba, “[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development],” Postepy Hig. Med. Doswiadczalnej Online, vol. 61, pp. 612–626, Oct. 2007.

[ii] M. Heffernan et al., “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice,” Endocrinology, vol. 142, no. 12, Art. no. 12, Dec. 2001, doi: 10.1210/endo.142.12.8522.

[iii] M. Tang-Christensen, P. J. Larsen, J. Thulesen, J. Rømer, and N. Vrang, “The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake,” Nat. Med., vol. 6, no. 7, pp. 802–807, Jul. 2000, doi: 10.1038/77535.

[iv] L. Blonde et al., “Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes,” Diabetes Obes. Metab., vol. 8, no. 4, pp. 436–447, Jul. 2006, doi: 10.1111/j.1463-1326.2006.00602.x.

[v] C. Lee, K. H. Kim, and P. Cohen, “MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism,” Free Radic. Biol. Med., vol. 100, pp. 182–187, Nov. 2016, doi: 10.1016/j.freeradbiomed.2016.05.015.

[vi] K. H. Kim, J. M. Son, B. A. Benayoun, and C. Lee, “The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress,” Cell Metab., vol. 28, no. 3, pp. 516-524.e7, Sep. 2018.

[vii] H. Neelakantan et al., “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice,” Biochem. Pharmacol., vol. 147, pp. 141–152, Jan. 2018, doi: 10.1016/j.bcp.2017.11.007.

[viii] B. G. Tchang et al., “Weight Loss Outcomes With Telemedicine During COVID-19,” Front. Endocrinol., vol. 13, p. 793290, 2022, doi: 10.3389/fendo.2022.793290.

[ix] D. H. Ryan, “Drugs for Treating Obesity,” Handb. Exp. Pharmacol., Nov. 2021.

[x] A. Astrup, D. H. Meier, B. O. Mikkelsen, J. S. Villumsen, and T. M. Larsen, “Weight loss produced by tesofensine in patients with Parkinson’s or Alzheimer’s disease,” Obes. Silver Spring Md, vol. 16, no. 6, Art. no. 6, Jun. 2008, doi: 10.1038/oby.2008.56.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy